Sponsored projects


Kempegowda Institute of Medical Sciences (KIMS),
Bangalore-560070 Department of Community Medicine

List of sponsored projects

Sl.No

Title of the Project

Year

Principal Investigator

Sponsors

1

An evaluation of vaccination coverage of children in rural community

1985

Dr. M. K. Sudarshan

Karnataka state council for science and technology (KSCST)

2

Coverage evaluation survey of immunization programme in Bangalore urban district

1989

Dr. M. K. Sudarshan

UNICEF, Hyderabad

3

Epidemiological survey of water borne diseases in the Karnataka region of Kaveri basin

1990

Dr. M. K. Sudarshan

Ministry of Environment & Forests, Govt. of India / Bangalore University

4

An epidemiological study of rabies in Bangalore city

1992

Dr. M. K. Sudarshan

Karnataka state council for science and technology (KSCST)

5

An evaluation of cold chain system for vaccines in the city of Bangalore

1992

Dr. M. K. Sudarshan

Karnataka state council for science and technology (KSCST)

6

An estimation of manpower and material requirement for a new primary health center- K. Gollahally, Bangalore urban district, Karnataka state, India

1993

Dr. M. K. Sudarshan

WHO-SEARO/ NIHFW, New Delhi

7

A sero-epidemiological survey of HIV among jail inmates in Bangalore

1994

Dr. M. Sundar

Karnataka state council for science and technology (KSCST)

8

Clinical evaluation of safety & immunogenicity of PCEC rabies vaccine (Kaketsuken) in post-exposure treatment

1994

Dr. M. K. Sudarshan

Serum Institute of India, Pune.

9

Multi indicator coverage evaluation survey (MIS) of Chitradurga district, Karnataka

1996

Dr. M. Sundar

Govt. of Karnataka / UNICEF, Hyderabad

10

Multi-indicator coverage evaluation survey (MIS) of Bangalore rural district

1996

Dr. M. S. Rajanna

Govt. of Karnataka / UNICEF, Hyderabad

11

Clinical evaluation of safety and efficacy of PVRV (Verorab) in post exposure treatment during pregnancy

1996

Dr. M. K. Sudarshan

Pasteur Merieux Connaught,France

12

Clinical evaluation of safety and immunogenicity of inactivated Hepatitis ‘A’ vaccine (Avaxim) in adults – Phase-III clinical trial

1997

Dr. M. K. Sudarshan

Pasteur Merieux Connaught, France

13

Evaluation of pulse polio immunization and routine immunization in Karnataka state

1998

Dr. M. S. Rajanna

UNICEF, Hyderabad

14

Evaluation on safety and efficacy of Albendazole in intestinal helminthiasis

1998

Dr. M. K. Sudarshan

Juggat Pharma, Bangalore

15

Evaluation of baby friendly hospitals in Karnataka

1998

Dr. M. K. Sudarshan

Breastfeeding promotion network of India (BPNI) /UNICEF

16

Clinical evaluation of safety and immunogenicity of Rhesus Diploid Rabies Vaccine (RDRV) in man

1999

Dr. M. K. Sudarshan

Serum Institute of India, Pune.

17

Screening of neonates and children for blood lead levels in KIMS- Project Lead free

1999

Dr. M. K. Sudarshan

George Foundation, USA

18

Comparative evaluation of tolerance and acceptability of DTaP vaccine with DTwP and DT as second booster at five years

2000

Dr. M. K. Sudarshan

Aventis Pasteur, France

19

A phase III open, comparative clinical trial to assess the safety and immunogenicity of Human Diploid Cell Vaccine (HDCV)(Adsorbed) manufactured by SII, Pune with standard commercially available HDCV rabies vaccine

2001

Dr. M. K. Sudarshan

Serum Institute of India, Pune.

20

National multi-centric study on monitoring of quality of iodized salt to prevent IDD and increase production of iodized salt through networking of medical colleges in South India ( two districts of Karnataka)

2001

Dr.D. H. Ashwath Narayana

Government of India

21

Improvisation of management information system (MIS) ofIndia population project VIII- urban health centers in Bangalore city

2001

Dr. M. K. Sudarshan

World Bank/BMP

22

A phase III open, comparative clinical trial to assess the safety and immunogenicity of Human Diploid Cell Vaccine (HDCV) (Lyophilized- Pittman Moore strain) manufactured by SII, Pune with standard commercially available HDCV (Lyophilized) of Aventis Pasteur in post exposure treatment

2002

Dr. M. K. Sudarshan

Serum Institute of India, Pune.

23

Morbidity and mortality survey and health seeking behavior in urban and rural field practice area of KIMS

2003

Dr.D.H. Ashwath Narayana

NIHFW, New Delhi

24

Validation of early diagnosis and prevention system software (EDPS) using computers at PHC, Kengeri

2003

Dr. M. K. Sudarshan

John Hopkins & George Foundation, USA.

25

A phase IV, open label, comparative clinical trial to assess the efficacy of Human Diploid Cell Rabies Vaccine (Adsorbed) with that of standard commercially available Human Diploid cell Rabies Vaccine (Lyophilized) in post exposure Rabies treatment

2004

Dr. M. K. Sudarshan

Serum Institute of India, Pune

26

A phase IV, open label, comparative clinical trial to assess the efficacy of Human Diploid Cell Rabies Vaccine (Lyophilized) with that of standard commercially available Human Diploid cell Rabies Vaccine (Lyophilized) in post exposure rabies treatment

2004

Dr. M. K. Sudarshan

Serum Institute of India, Pune

27

A phase IV, post marketing surveillance study to assess the immunogenicity and reactogenicity of Human Diploid cell Rabies vaccine (Adsorbed, Rabivax ) manufactured by Serum Institute of India.

2004

Dr. M. K. Sudarshan

Serum Institute of India, Pune

28

An open label, phase IV, comparative clinical trial to assess the safety and efficacy of Human Diploid Cell rabies Vaccine (liquid) (Rabivax) with Purified Chick Embryo Cell (PCEC) rabies vaccine (Rabipur)

2004

Dr. M. K. Sudarshan

Serum Institute of India, Pune.

29

Assessing burden of rabies in India- A national multicentric rabies survey

2004

Dr. M. K. Sudarshan

WHO-APCRI

30

A multicenter study to assess the safety & immunogenicity of Vaxirab in post-exposure cases

2005

Dr. B. J. Mahendra

Cadila Healthcare Ltd., Ahmedabad

31

A multicenter study to assess the Safety and Immunogenicity of Vaxirab Vs Lyssavac N Berna in simulated post-exposure prophylaxis

2005

Dr. B. J. Mahendra

Cadila Healthcare Ltd. Ahmedabad

32

A phase IV, single center, randomized, open-label, parallel group immunogenicity and reactogenicity study in healthy volunteers, comparing PCECV(Rabipur) administered intradermally at two sites in a dose of 0.1ml per site or PCECV dministered intramuscularly at a dose of 1.0ml, both on 0,3,7,14,28 (Essen post-exposure scheme)

2005

Dr. M. K. Sudarshan

Chiron vaccines, Germany

33

A multi center, phase III, randomized, double blind comparative study to evaluate the safety & immunogenicity of rabies vaccine (Indirab) in animal bite cases- anequivalence trial

2007

Dr. B. J. Mahendra

Bharat Biotech International Ltd, Hyderabad

34

A performance audit of animal birth control (ABC) programme in Bangalore city

2007

Dr. M. K. Sudarshan

Bruhat Bangalore Mahanagara palike

35

Prevalence of food allergy in urban & rural of Bangalore – An Euro Prevall study.

2007

Dr. B. G. Parasuramalu

Institute of food research (IFR), United Kingdom

36

Clinical evaluation of safety & immunogenicity of purified chick embryo cell rabies vaccine administered intradermally using updated TRC regimen (2-2-2-0-2) in animal bite cases.

2007

Dr.D. H. Ashwath Narayana

Novartis Vaccines, Mumbai, India

37

Assessing the burden of bronchial asthma in rural adult population

2008

Dr. B. G. Parasuramalu

RGUHS, Bangalore

38

Clinical evaluation of safety & immunogenicity of Indirab & Verorab vaccines using updated Thai Red Cross regimen in healthy volunteers: Phase III, randomized clinical study

2008

Dr.D. H. Ashwath Narayana

Bharat Biotech International Ltd, Hyderabad

39

A comparative multi centre study to assess the immunogenicity and safety of PDEV (Vaxirab) versus PCEC Vaccine (Rabipur) and PVRV (Verorab) in post exposure cases

2008

Dr.D. H. Ashwath Narayana

Cadila Health Care, Ahmedabad

40

An open label study to assess the safety &immunogenicity of PCECPM vaccine administred intramuscularly using pre exposure vaccination in healthy volunteers.

2009

Dr.D. H. Ashwath Narayana

Cadila Healthcare Ltd. Ahmedabad

41

An open label study to assess safety & immunogenicity of PCECPM vaccine administred intramuscularly using simulated post exposure prophylaxis

2009

Dr.D. H. Ashwath Narayana

Cadila Healthcare Ltd. Ahmedabad

42

Adopt a Village – A rural rabies prevention project

2009

Dr M K Sudarshan- Advisor Dr.D. H. Ashwath Narayana– Project Coordinator Dr.N. R. Ramesh Masthi – Project officer (Medical)

Global alliance for rabies control (GARC), USA; Rabies in Asia (RIA)Foundation &Commonwealth Veterinary Association (CVA)

43

An open label, multicentric study to assess safety & immunogenicity of PCECPM vaccine administred intramuscularly using PEP in animal bite cases

2010

Dr.D. H. Ashwath Narayana

Cadila Healthcare, Ahmedabad

44

Clinical evaluation of safety & immunogenicity of PCECPM vaccine administred intradermally using updated TRC regimen in healthy volunteers

2010

Dr.D. H. Ashwath Narayana

Cadila Healthcare, Ahmedabad

45

Comparative study to assess the safety & immunogenicity of PCECV & PVRV rabies vaccines administred intradermally using new one week regimen (4-4-4-0-0) in healthy volunteers

2010

Dr.D. H. Ashwath Narayana

Rabies in Asia- India Chapter

46

Safety and immunogenicity study for use of Meningococcal (Groups A,C,Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra) in healthy subjects 2-55 years of age in India.

2010

Dr.M. K. Sudarshan & Dr.D. H. Ashwath Narayana

Sanofi Pasteur, France

47

What’s on my hands study

2010

Dr.Jayanthi Srikanth

Indian Public Health Association & HUL (Life buoy division)

48

A phase IV, multi-center, randomized, open-label study of PCECV (Rabipur®) comparing the immunogenicity and safety of two different simulated post exposure schedules (Zagreb 2-1-1 vs Essen regimen 1-1- 1-1-1) in Healthy Indian subjects

2011

Dr.D. H. Ashwath Narayana

Novartis vaccines

49

Comparative study on safety & Immunogenicity of Vaxirab-N vs

Rabipur

2012

Dr. H. S. Ravish

Cadila Health care Pvt. Ltd.

50

Situational analysis of health professionals education in India

2012

Dr. D. H Ashwath Narayana

Public Health Foundation of India, New Delhi

51

Prospective dengue seroprevalence study in 5 to 10 year old children in India

2012

Dr. N. R. Ramesh Masthi

Sanofi Pasteur

52

A Phase II/III randomized, multi-centric, comparator-controlled study of the safety and neutralizing activity of a human monoclonal antibody to rabies (SII RMAb) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure.

2013

Dr. D. H Ashwath Narayana

Serum Institute of India, Pune

53

Assessing safety and immunogenicity of PCECV (Rabipur) and PVRV (Verorab) administered using one week intra dermal regimen (4-4-4) in animal bite cases.

2013

Dr. D. H Ashwath Narayana

Rabies in Asia Foundation

54

Occupational Asthma in silk workers

2014

Dr. Giriyanna Gowda

Medical Education & Research Trust, Bangalore

55

Immunogenicity and safety of rabies G protein vaccine administered as simulated post-exposure immunization in healthy volunteers

2016

Dr. H. S. Ravish

Cadila Pharmaceutical Ltd, Ahmedabad

56

Respiratory morbidities among school children post Diwali in Bangalore city

2018

Dr. Giryanna Gowda

Medical Education & Research Trust, Bangalore